|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
Opexa Therapeutics, Inc., 2635 Technology Forest Blvd, The Woodlands, Texas 77381, US
|
|
Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis as well as other autoimmune diseases, such as neuromyelitis optica. These therapies are based on Opexa's proprietary T-cell technology. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis. Top-line results from the Abili-T trial are expected in early 4th quarter of 2016.
Opexa’s mission is to lead the field of Precision Immunotherapy® by aligning the interests of patients, employees and shareholders.
|
Opexa Therapeutics Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
100%
|
The widely used Opexa Therapeutics email format is {f}{last} (e.g. [email protected]) with 100% adoption across the company.
To contact Opexa Therapeutics customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.